Synthemed REPEL-CV trial shows promise
This article was originally published in Clinica
Executive Summary
Synthemed's bioresorbable adhesion barrier for use in cardiac surgery, the REPEL CV, has yielded positive results in an EU clinical study. The firm hopes that the results will boost its chances at being the first company to get such a product to market, it announced last week.